Bladder cancer

Managing adverse events of systemic therapies in muscle-invasive and metastatic UCa

Last updated: 28.08.2026

Solve cases and receive feedback

Case 1 - mUCa, ocular symptoms resolved after erdafitinib withheld

Case 2 - mUCa, grade 2 colitis while on IO

Case 3 - mUCa, grade 3 colitis while on IO

Case 4 - mUCa, grade 2 maculopapular rash while on EV+P

Case 5 - MIBC, grade 2 pneumonitis while on IO

Case 6 - mUCa, grade 2 peripheral neuropathy while on EV

Case 7 - mUCa, grade 2 central serous chorioretinopathy while on targeted therapy

Follow a course and earn CME credits

Earn CME credits by running a case series and completing an assessment. Many topics available for various disease areas. And all for free!

Start a course